NUREXONE BIOLOGIC INC. Financial Flexibility Index
NUREXONE BIOLOGIC INC. financial flexibility index. NUREXONE BIOLOGIC INC. (J90) has a Financial Flexibility Index of -0.88x as of December 2025. Free cash flow of €-1.17 Million (operating CF €-1.17 Million minus capex €9.00K) represents -1% of total liabilities (€1.32 Million).
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of NUREXONE BIOLOGIC INC. (2021–2025)
Financial flexibility index of NUREXONE BIOLOGIC INC. from 2021 to 2025. Historical Financial Flexibility Index trend for NUREXONE BIOLOGIC INC. across 5 annual periods. Explore NUREXONE BIOLOGIC INC. cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
NUREXONE BIOLOGIC INC. Financial Flexibility Index by Year (2021–2025)
NUREXONE BIOLOGIC INC. financial flexibility index by year from 2021 to 2025. Year-by-year free cash flow to debt coverage for NUREXONE BIOLOGIC INC.. For the full cash flow conversion analysis, see NUREXONE BIOLOGIC INC. cash conversion from operations.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -3.36x | €-4.46 Million | €-4.51 Million | €1.32 Million | ▲ +46.1% |
| 2024 | -6.23x | €-4.24 Million | €-4.89 Million | €680.00K | ▼ -337.8% |
| 2023 | -1.42x | €-2.82 Million | €-2.94 Million | €1.98 Million | ▲ +73.8% |
| 2022 | -5.44x | €-3.80 Million | €-3.85 Million | €698.00K | ▼ -632.3% |
| 2021 | -0.74x | €-1.23 Million | €-1.23 Million | €1.66 Million | — |